Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Early Treatment Strategy With High-dose Dexamethasone in Patients With SARS-CoV-2
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Hospital Universitario Infanta Leonor
- Target Recruit Count
- 200
- Registration Number
- NCT05293210
Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Conditions
- Myelodysplastic Syndromes, SecondaryMyelodysplastic Syndromes, Previously TreatedTreatment-Related Acute Myeloid LeukemiaTherapy-Related Myelodysplastic SyndromeAcute Lymphoblastic Leukemia With Failed RemissionMyelodysplastic Syndromes, de NovoLymphoblastic Lymphoma, in RelapseAcute Leukemia of Ambiguous Lineage in RelapseLymphoblastic Lymphoma, RefractoryAcute Leukemia of Ambiguous Lineage
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Andrew E. Place, MD
- Target Recruit Count
- 92
- Registration Number
- NCT05292664
- Locations
- 🇺🇸
University of California San Francisco-Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Intrathecal Pemetrexed for Leptomeningeal Metastasis
- Conditions
- Interventions
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 34
- Registration Number
- NCT05289908
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 16
- Registration Number
- NCT05289492
- Locations
- 🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸Eastern Connecticut Hematology & Oncology, Norwich, Connecticut, United States
🇧🇪ZNA Cadix, Antwerp, Belgium
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 17
- Registration Number
- NCT05288062
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT05286814
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT05285813
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Comparative Study Between the Prophylactic Intravenous Administrations of Acetaminophen vs Dexamethasone vs Pethidine Regarding the Incidence of Shivering Induced by Single Shot Spinal Anesthesia in the Orthopedic Surgeries of the Lower Limbs
- Conditions
- Interventions
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 108
- Registration Number
- NCT05284409
- Locations
- 🇪🇬
Ain Shams University Hospitals, Cairo, Egypt
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 36
- Registration Number
- NCT05280275
- Locations
- 🇬🇷
Anticancer Hospital of Thessaloniki "Theageneio", Thessaloniki, Greece
🇬🇷Department of Clinical Therapeutics, School of Medicine, National Kapodistrian University of Athens (NKUA), Athens, Greece
Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Democritus University of Thrace
- Target Recruit Count
- 150
- Registration Number
- NCT05279391
- Locations
- 🇬🇷
University Hospital of Alexandroupolis, Alexandroupolis, Evros, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.